← Back to patent-cliff list
AZR-MD-001
Tier C — Watch / tradeAZR-MD-001
Azura Ophthalmics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Dry eye syndrome, Dry eye disease, 睑板腺功能障碍
Regional status
US
Phase III
2024-05-28
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZR-MD-001?
Approved indications include: Dry eye syndrome, Dry eye disease, 睑板腺功能障碍.
When does the AZR-MD-001 patent expire?
No public expiry year is available for AZR-MD-001 yet; this page updates once verified.
How do I get a quote for AZR-MD-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06